Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

Mostrar otras versiones (1)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) are among the treatments recommended for high-risk ambulatory persons with coronavirus 2019 (COVID-19). Here, we study viral culture dynamics post-treatment in a subset of participants receiving the mAb bamlani...

Descripción completa

Detalles Bibliográficos
Autores principales: Boucau, Julie, Chew, Kara W., Choudhary, Manish C., Deo, Rinki, Regan, James, Flynn, James P., Crain, Charles R., Hughes, Michael D., Ritz, Justin, Moser, Carlee, Dragavon, Joan A., Javan, Arzhang C., Nirula, Ajay, Klekotka, Paul, Greninger, Alexander L., Coombs, Robert W., Fischer, William A., Daar, Eric S., Wohl, David A., Eron, Joseph J., Currier, Judith S., Smith, Davey M., Li, Jonathan Z., Barczak, Amy K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213028/
https://www.ncbi.nlm.nih.gov/pubmed/35793677
http://dx.doi.org/10.1016/j.xcrm.2022.100678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213028/
https://www.ncbi.nlm.nih.gov/pubmed/35793677
http://dx.doi.org/10.1016/j.xcrm.2022.100678

Ejemplares similares